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Abstract
Introduction: Clinical diversity in systemic sclerosis (SSc) reflects multifaceted pathogenesis and the effect of key
growth factors or cytokines operating within a disease-specific microenvironment. Dermal interstitial fluid sampling
offers the potential to examine local mechanisms and identify proteins expressed within lesional tissue. We used
multiplex cytokine analysis to profile the inflammatory and immune activity in the lesions of SSc patients.
Methods: Dermal interstitial fluid sample from the involved forearm skin, and synchronous plasma samples were
collected from SSc patients (n =26, diffuse cutaneous SSc (DcSSc) n =20, limited cutaneous SSc (LcSSc) n= 6), and
healthy controls (HC) (n =10) and profiled by Luminex® array for inflammatory cytokines, chemokines, and growth factors.
Results: Luminex® profiling of the dermal blister fluid showed increased inflammatory cytokines (median interleukin ( IL)-6
in SSc 39.78 pg/ml, HC 5.51 pg/ml, p=0.01, median IL-15 in SSc 6.27 pg/ml, HC 4.38 pg/ml, p= 0.03), chemokines
(monocyte chemotactic protein (MCP)-3 9.81 pg/ml in SSc,7 . 1 8p g / m lH C ,p=0 . 0 4 ) ,a n dp r o f i b r o t i cg r o w t hf a c t o r s
(platelet derived growth factor (PDGF)-AA 10.38 pg/ml versus 6.94 pg/ml in HC, p=0.03). In general dermal fluid and
plasma cytokine levels did not correlate, consistent with predominantly local production of these factors within the
dermal lesions, rather than leakage from the serum. In hierarchical clustering and network analysis IL-6 emerged as a key
central mediator.
Conclusions: Our data confirm that an immuno-inflammatory environment and aberrant vascular repair are intimately
linked to fibroblast activation in lesional skin in SSc. This non-invasive method could be used to profile disease activity in
the clinic, and identifies key inflammatory or pro-fibrotic proteins that might be targeted therapeutically. Distinct
subgroups of SSc may be defined that show innate or adaptive immune cytokine signatures.
Introduction
Clinical heterogeneity in systemic sclerosis (SSc) and vari-
ation in response to therapy is likely to reflect diverse
underlying pathogenic mechanisms. Whole skin gene ex-
pression profiling has classified distinct molecular subsets
with proliferative, fibrotic, limited and normal-like mRNA
signatures [1] and associated these with possible treatment
response to immunosuppression [2]. Response to therapy
in SSc has traditionally been assessed by the modified
Rodnan skin score [3], in addition to clinical and labora-
tory measures of organ function, and these have proven
very valuable in clinical trials and pragmatic in routine
clinical practice, but are not specifically linked to under-
lying biologic activity. Biomarker assays would allow for
sensitive and reproducible means of targeting therapy and
assessing disease response. Methods that define the mo-
lecular changes in lesional tissue of patients are needed
and could link well with specific targeted treatments [4].
Gene expression biomarkers have been correlated with
change in skin score [5] and, although not extensively
studied, subset signatures have tended to be stable over
time [1]. The aim of this study was to directly examine
protein expression within the dermal interstitial fluid
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this with circulating levels.
The dermal suction blister method is a minimally inva-
sive technique of sampling interstitial fluid. Søndergaard
and colleagues developed the technique in SSc, noting in-
creased levels of soluble intercellular adhesion molecule-1
and soluble interleukin (IL)-2 receptor in the interstitial
fluid compared with the serum, mainly in the transition
zone of the dermis [6].
Here we have used the novel approach of dermal suc-
tion blister fluid sampling combined with multiplex ana-
lysis to investigate protein expression within the dermal
interstitial fluid in a well-characterised cohort of SSc pa-
tients and representative healthy controls (HCs). We
have specifically compared the levels of key candidate
proteins that may be relevant to pathogenesis or may re-
flect disease severity or activity. In addition we have
compared the results for serum and dermal blister fluid
samples within individual patients. This robust method
has provided data that confirm the utility of this ap-
proach and highlighted potentially important aspects of
disease biology. This approach could enable clinically
useful biomarkers and allow application of targeted ther-
apies to those most likely to benefit, based on the pat-
tern of growth factor and cytokine expression.
Methods
Sample collection
Interstitial fluid samples from the forearm skin of patients
with scleroderma and HCs were collected using the dermal
suction blister method. The patients were all under the care
of the Royal Free Hospital Centre for Rheumatology and
Connective Tissue Diseases. All subjects provided informed
consent, and this study was approved by the Local Research
Ethics Committee (see Acknowledgements for details). The
technique involved a dermal suction machine (Ventipress,
Upsalla, Sweden) being adhered to newly sterilised forearm
skin. The machine was attached to a clinic vacuum line and
left for 2.5 hours, with suction pressure 280 mmHg through
an 8 mm suction cup. Interstitial fluid was removed using a
23 gauge needle and stored in aliquots at −80°C. Between
100 and 250 μl blister fluid were collected from each pa-
tient. Plasma samples were obtained for each case, as close
to the time of blister sampling as feasible. Plasma was ali-
quoted and frozen at −80°C for later analysis.
Clinical details on the patients were collected, which
included type of disease, gender, age, date of disease on-
set, antibody status, current treatment, prior treatment,
organ involvement, most recent forced vital capacity and
forced expiratory volume in 1 second, recent creatinine,
recent estimated pulmonary artery pressure on echocar-
diogram, and recent N-terminal brain natriuretic protein
results. These data are all routinely tested on our cohort
of patients as best practice.
Sample analysis
Both the plasma and interstitial fluid samples were profiled
by Luminex® (Life Technologies, Paisley, UK) bead array for
inflammatory cytokines, chemokines, and growth factors
including factors previously implicated in SSc pathogenesis
(41 factors were analysed; see Tables 1 and 2). One aliquot
of plasma and one aliquot of serum were analysed per
subject.
Data analysis
Permutation analysis was used to compare cytokine levels
in SSc and HC samples. This was processed in Excel
(Microsoft, Redmond, Washington), and analysed using
Wilcoxon rank-sum tests and significance analysis of
microarray correction [7]. Where samples were undetect-
able below the threshold, the lowest detectable level was
assigned; and where sample concentrations were greater
than the range available for analysis, they were assigned the
upper limit value of the range. Spearman’s rank correlation
was used to assess any correlation between serum and
interstitial fluid cytokine and growth factor levels. Hierarch-
ical clustering and heat map construction was performed
with CIMminer (Bethesda, Maryland, USA) using correl-
ation to cluster both patients and protein factors. One-way
analysis of variance with post hoc analysis was applied to
the subgroup analysis derived from the hierarchical
clustering.
Network of potential protein interactions
Using the STRING 9.1 database (Swiss Institute of Bioinfor-
matics, Lausanne, Switzerland), networks of potential pro-
tein interactions were created using the inflammatory
proteins that were found to be significantly raised in the
hierarchical clustering from our analysis, and were ex-
panded to include downstream targets.
Results
Patients
In total, 26 patients with SSc were included in the ana-
lysis and 10 HCs. The clinical and laboratory features of
the patients are presented in Table 3.
The mean age of the SSc patients was 55 years (standard
deviation (SD) 10). Eight SSc subjects were male and 18
were female. Twenty SSc patients were classified as diffuse
cutaneous systemic sclerosis (DcSSc) and six had limited
cutaneous systemic sclerosis (LcSSc). The mean duration of
disease, defined by first non-Raynaud’s manifestation of
SSc, was 9 years (SD 7.85), with a range from 1 to 33 years.
Five patients had early disease, defined as disease duration
<2 years. The mean modified Rodnan skin score of patients
was 18.3 (SD 11.2). The mean age of control subjects was
51 years (SD 14). Nine HCs were female and one was male.
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Biologic function Healthy control samples SSc samples P value
Innate immunity IFNα2 5.34 (4.4 to 7.61) 6.35 (4.81 to 7.52) 0.35
IL-1α 74.77 (22.48 to 132.28) 40.42 (15.27 to 113.19) 0.44
IL-1B 0.37 (0.37 to 1.62) 0.62 (0.37 to 1.62) 0.57
IL-1RA 802.5 (469.25 to 1,796.5) 695 (499.5 to 1,075.5) 0.72
IL-6 5.51 (2.44 to 26.83) 38.78 (19.23 to 88.81) 0.01
IL-12p40 5.16 (4.39 to 6.11) 4.58 (4.39 to 7.6) 0.86
IL-12p70 2.03 (1.74 to 2.21) 1.99 (1.72 to 2.34) 0.87
IL-15 4.38 (3.2 to 4.95) 6.27 (4.21 to 9.34) 0.03
IP-10 988.5 (510.5 to 1,172.25) 1054 (547.25 to 1,929) 0.44
TNFα 25.95 (12.15 to 65.36) 22.19 (14.46 to 44.1) 0.92
Adaptive immunity IFNʳ 1.23 (1.12 to 2.76) 1.58 (1.33 to 2.76) 0.19
IL-2 1.26 (0.73 to 1.26) 1.26 (0.64 to 1.31) 0.57
IL-3 1.62 (1.14 to 1.62) 1.62 (1.1 to 1.62) 0.78
IL-4 2.6 (1.72 to 5.24) 3.955 (2.18 to 5.24) 0.54
IL-5 1.28 (0.84 to 1.72) 0.96 (0.84 to 1.72) 0.83
IL-7 4.16 (2.99 to 5.59) 4.89 (3.52 to 7.94) 0.13
IL-9 0.77 (0.77 to 1.94) 0.77 (0.77 to 1.94) 0.86
IL-10 22.02 (16.77 to 40.28) 33.05 (12.91 to 44.83) 0.83
IL-13 1.95 (1.67 to 2.8) 1.98 (1.66 to 2.8) 0.81
IL-17a 1.23 (1.23 to 1.34) 1.23 (1.23 to 1.34) 0.78
sCD40L 284.5 (207.5 to 466.5) 285 (204.75 to 483) 0.83
TNFʲ 1.04 (1.04 to 3.95) 1.04 (1.04 to 3.95) 0.97
Chemokines Eotaxin 37.95 (21.05 to 48.53) 31.46 (26.64 to 48.93) 0.92
Fractalkine 37.96 (30.03 to 52.69) 39.61 (22.83 to 48.54) 0.62
GRO 69.91 (47.16 to 252) 129 (78.92 to 246.25) 0.31
IL-8 61.85 (28.05 to 234.75) 51.69 (37.24 to 80.03) 0.66
MCP-1 762.5 (544 to 1,661.25) 792 (668.75 to 1,340.5) 0.92
MCP-3 7.18 (5.7 to 9.81) 9.81 (7.5 to 10.66) 0.04
MDC 1004.5 (715 to 1,126.75) 695 (554.5 to 867.25) 0.10
MIP-1α 21.21 (3.51 to 47.18) 10.5 (3.51 to 16.46) 0.31
MIP-1ʲ 43.44 (8.13 to 111.17) 24.42 (12.89 to 45.65) 0.46
RANTES 47.21 (19.68 to 178.01) 55.76 (33.4 to 101.35) 0.71
Growth factors EGF 2.72 (2.72 to 10.12) 2.72 (2.72 to 7.25) 0.58
Flt-3 L 70.25 (4.16 to 82.49) 51.82 (23.89 to 77.59) 0.45
GCSF 3.26 (3.24 to 16.04) 3.24 (3.23 to 12.33) 0.69
GMCSF 2.79 (1.88 to 9.33) 2.22 (1.74 to 7.24) 0.63
PDGF-AA 6.94 (5.87 to 7.78) 10.38 (7.4 to 17.71) 0.03
PDFG-BB 1.79 (0.41 to 1.79) 1.79 (1.79 to 3.2) 0.23
TGF-α 7.09 (6.64 to 8.21) 7.0 (5.62 to 9.1) 0.62
FGF-2 13.4 (11.67 to 16.8) 16.92 (13.4 to 20.24) 0.09
VEGF 11.3 (6.92 to 16.92) 11.67 (10.28 to 22.29) 0.47
Data presented as median concentration (pg/ml) (25th to 75th percentile). Permutation analysis: significance analysis of microarrays for Excel, Wilcoxon rank-sum
test. Significant results are in bold, taken as P <0.05. EGF, epidermal growth factor; FGF, fibroblast growth factor; Flt, FMS-like tyrosine kinase; GCSF, granulocyte
colony-stimulating factor; GMCSF, granulocyte–macrophage colony-stimulating factor; GRO, growth regulated oncogene; IFN, interferon; IL, interleukin; IL-1RA,
interleukin-1 receptor antagonist; IP-10, Interferon gamma induced protein 10; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; PDGF,
platelet-derived growth factor; RANTES, regulated on activation normal T cell expressed and secreted; SSc, systemic sclerosis; TGF-ʱ, transforming growth factor
alpha; TNF-ʱ, tumour necrosis factor alpha; VEGF, vascular endothelial cell growth factor.
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Biologic function Healthy control samples SSc samples P value
Innate immunity IFNα2 20.16 (14.47 to 29.72) 28.86 (18.41 to 39.83) 0.33
IL-1α 2.51 (2.51 to 5.78) 2.51 (2.51 to 17.91) 0.37
IL-1B 1.65 (1.65 to 1.65) 1.65 (1.65 to 1.72) 0.40
IL-1RA 34.52 (25.15 to 44.60) 57.36 (35.85 to 83.9) 0.03
IL-6 2.66 (2.66 to 2.66) 2.66 (2.66 to 2.69) 0.29
IL-12p40 4.77 (4.77 to 5.63) 12.92 (4.77 to 28.25) 0.07
IL-12p70 3.78 (2.97 to 5.64) 4.73 (3.46 to 7.78) 0.34
IL-15 2.45 (2.45 to 2.45) 2.45 (2.45 to 2.76) 0.29
IP-10 297 (189.75 to 448) 396 (317.5 to 544.5) 0.27
TNFʱ 4.38 (3.98 to 6) 6.98 (4.98 to 8.84) 0.04
Adaptive immunity IFNʳ 3.7 (2.99 to 4.49) 4.89 (3.26 to 6.82) 0.38
IL-2 1.47 (1.47 to 1.47) 1.47 (1.47 to 2.14) 0.29
IL-3 0.36 (0.34 to 0.54) 0.57 (0.34 to 0.82) 0.54
IL-4 2.83 (2.83 to 2.83) 2.83 (2.83 to 3.65) 0.20
IL-5 1.93 (1.93 to 1.93) 1.93 (1.93 to 1.93) 0.52
IL-7 2.28 (1.78 to 2.89) 2.66 (2.14 to 3.85) 0.47
IL-9 1.24 (1.24 to 1.24) 1.24 (1.24 to 1.24) 0.40
IL-10 1.55 (1.03 to 2.91) 2.86 (1.48 to 5.18) 0.13
IL-13 1.65 (1.65 to 1.65) 1.65 (1.65 to 1.65) 0.40
IL-17α 2.33 (1.75 to 2.38) 2.49 (1.61 to 3.38) 0.38
sCD40L 9,800.01 (9,800.01 to 9,800.01) 9,800.01 (9,800.01 to 9,800.01) 0.87
TNFʲ 2.34 (2.34 to 2.76) 2.34 (2.34 to 3.26) 0.49
Chemokines Eotaxin 95.3 (67.43 to 129.75) 97.64 (76.3 to 132.5) 0.87
Fractalkine 50.87 (41.87 to 57.36) 62.72 (49.39 to 72.85) 0.21
GRO 627.5 (477.25 to 655) 556 (383.5 to 709) 0.52
IL-8 3.11 (1.97 to 4.32) 3.29 (2.78 to 4.07) 0.58
MCP-1 236.5 (217.5 to 240.5) 230 (157.5 to 274) 0.83
MCP-3 8.84 (5.73 to 13.41) 14.68 (8.63 to 19.76) 0.06
MDC 718 (686.75 to 785.5) 696 (624 to 835) 0.71
MIP-1α 1.6 (1.6 to 2.03) 1.77 (1.6 to 3.99) 0.24
MIP-1ʲ 18.47 (16.15 to 24.73) 21.92 (17.75 to 27.85) 0.52
RANTES 1,869 (1,723.5 to 2,090.5) 1,473 (1,234 to 1,626) 0.01
Growth factors EGF 49.36 (38.36 to 144.75) 63.8 (47.29 to 128) 0.83
Flt-3 L 5.07 (5.07 to 5.07) 5.07 (5.07 to 5.59) 0.29
GCSF 35.64 (33.17 to 39.41) 43.21 (34.88 to 54.04) 0.21
GMCSF 7.9 (6.04 to 10.71) 12.84 (9.15 to 20.06) 0.05
PDGF-AA 1,518.5 (889 to 1,852) 1,300 (825.5 to 1,601.5) 0.49
PDFG-BB 4,137 (2,686.5 to 5,063.75) 4,573 (3,646 to 5,609.5) 0.43
TGFα 0.41 (0.41 to 0.41) 0.41 (0.41 to 0.41) 0.40
FGF-2 59.52 (48.78 to 80.7) 78.75 (57.53 to 95.77) 0.12
VEGF 71.78 (50.92 to 91.04) 130 (81.12 to 202) 0.08
Data presented as median concentration (pg/ml) (25th to 75th percentile). Permutation analysis: significance analysis of microarrays for Excel, Wilcoxon rank-sum
test. Significant results are in bold, taken as P <0.05. EGF, epidermal growth factor; FGF, fibroblast growth factor; Flt, FMS-like tyrosine kinase; GCSF, granulocyte
colony-stimulating factor; GMCSF, granulocyte–macrophage colony-stimulating factor; GRO, growth regulated oncogene; IFN, interferon; IL, interleukin; IL-1RA,
interleukin-1 receptor antagonist; IP-10, Interferon gamma induced protein 10; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; PDGF,
platelet-derived growth factor; RANTES, regulated on activation normal T cell expressed and secreted; SSc, systemic sclerosis; TGF-ʱ, transforming growth factor
alpha; TNF-ʱ, tumour necrosis factor alpha; VEGF, vascular endothelial cell growth factor.
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The results of the interstitial fluid from the Luminex® array
are presented in Table 1. This array identified seven cyto-
kines whose mean concentrations were significantly higher
in the patient cohort compared with the HC group. These
cytokines included inflammatory cytokines (median IL-6:
SSc 38.78 pg/ml, HC 5.51 pg/ml, P =0.01; median IL-15:
S S c6 . 2 7p g / m l ,H C4 . 3 8p g / m l ,P=0.03), chemokines
(monocyte chemotactic protein (MCP)-3: SSc 9.81 pg/ml,
HC 7.18 pg/ml, P=0.04), vascular growth factors (fibroblast
growth factor (FGF)-2: SSc 16.92 pg/ml, HC 13.4 pg/ml, P
=0.09), and profibrotic growth factors (platelet-derived
growth factor (PDGF)-AA: SSc 10.38 pg/ml, HC 6.94 pg/
ml, P=0.03) (factors grouped by biologic function sum-
marised in Table 1) (significance analysis of microarray re-
vealed these to have at least a 1.45-fold increase compared
with controls).
Using Spearman rank correlation, there was no signifi-
cant correlation between the significant proteins in the blis-
ter fluid and skin score or disease duration. MCP-1 was
found to correlate negatively with disease duration (r=
−0.406, P=0.044). In addition we found that some factors
were specific to the SSc dermal blister fluid samples and
not detectable in HC samples. IL-17 was only detectable in
DcSSc (5/19), and in 0/6 LcSSc and 0/10 HC. IL-6 showed
a trend towards increased concentrations in DcSSc com-
pared with LcSSc, but this was not statistically significant
(mean 71.7 pg/ml in DcSSc, 32.3 pg/ml in LcSSc, P=0.07).
MCP-3 also showed a suggestion of concentrations in
DcSSc compared with LcSSc, but again this was not statisti-
cally significant (mean 7.93 pg/ml in DcSSc, 6.09 pg/ml in
LcSSc, P=0 . 36 ) .
Plasma samples
Plasma samples were available from 19/26 SSc patients
and 8/10 HCs, and these were included in the analysis. The
results from the Luminex® array are presented in Table 2.
Nine cytokines or chemokines were significantly raised in
SSc patients compared with HCs.T h ep r o t e i n st h a tw e r es i g -
nificantly raised in the serum (P <0.05) were IL-1 receptor
antagonist (median: SSc 57.36 pg/ml, HC 34.52 pg/ml, P=
0.03), tumour necrosis factor alpha (median: SSc 6.98 pg/ml,
HC 4.38 pg/ml, P=0.04), regulated on activation, normal T
cell expressed and secreted (median: SSc 1,473 pg/ml, HC
1,869 pg/ml, P=0.01), and granulocyte–macrophage colony-
stimulating factor (median: SSc 12.84 pg/ml, HC 7.9 pg/ml,
P=0.05). Using significant analysis of microarrays, MCP-3,
IL-12p40, vascular endothelial growth factor, IL-10, IL-4, IL-
2 and IL-1a were all found to have a greater than 1.5-fold in-
crease in concentrationc o m p a r e dw i t hH C s .
Of interest, T-helper type (Th) 2 cytokines IL-4, IL-5
and IL-13 were only detectable in SSc plasma, although
none of these were significant. IL-6 was also only detect-
able in SSc plasma, and not within HC plasma samples,
but again was not significant (P=0. 0 7) .
In total, 19/26 SSc patients had adequate samples for
paired analysis. Comparing the Luminex® array profiling
of the dermal blister fluid from those patients with SSc with
the paired serum samples, none of the correlations reached
significance. Other proinflammatory cytokines (IL-6: r
2=
0.083, P=0. 2 3;IL- 17 :r
2=0.02, P=0.56) and growth factors
(vascular endothelial cell growth factor: r
2=0.03, P=0.47;
PDGF: r
2=0.08, P=0.22) showed no correlation between
concentrations in the serum samples and in the dermal
blister fluid. This supports the notion that profiling the
dermal interstitial fluid reflects the local inflammatory pro-
file, as opposed to leakage from the serum [6].
The HCs showed greater correlation between the
Luminex® array results from the dermal blister fluid and
serum samples, with many reaching significance. These
included FGF-2 (r
2=0.58, P =0.03) and regulated on ac-
tivation normal T cell expressed and secreted (r
2=0.60,
P =0.02). Hierarchical clustering of plasma and blister
fluid samples is shown in Figure 1.
Hierarchical clustering
Protein concentrations were expressed as ratios of the
mean value, log transformed and then expressed as SD
Table 3 Demographic and clinical features of the study
cohort
Disease characteristics Systemic sclerosis
patients
Healthy
controls
(n=26) (n=10)
Age (years) 55± 10 51±14
Female sex 18 (69) 9 (90)
Diffuse cutaneous systemic sclerosis 20 (77)
Disease duration (months) 9±7.9
Duration of Raynaud’s (months) 10± 1.6
Modified Rodnan skin score 18.3±11.24
Organ involvement
Oesophageal 69.2
Other gastrointestinal 46.2
Lung 42.3
Muscle 30.8
Joint 11.5
Renal 3.8
Cardiac 7.7
Serology
Anti-nuclear antibody positive 100
Anti-RNA polymerase antibody 12
Anti-topoisomerase antibody 38
Anti-centromere antibody 15
Other 35
Data presented as mean ± standard deviation, n (%) or percentage.
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constructed for BF and plasma Luminex® results using
CIMminer NIH software. Unbiased clustering was
performed using correlation and the Pearson coefficient.
The length of the dendrogram is inversely proportional to
correlation. The resulting dendrogram shows clustering
Figure 1 Hierarchical clustering of plasma and blister fluid samples. Heat maps of blister fluid (a) and plasma (b) for systemic sclerosis (SSc)
patients characterised as limited cutaneous systemic sclerosis (LcSSc) or diffuse cutaneous systemic sclerosis (DcSSc). Blister fluid analysis was
associated with clustering of SSc patients into three groups; Group 1, mainly DcSSc and characterised as interleukin (IL)-6, IL-10, tumour necrosis factor
alpha (TNFα), and IL-1α high (innate inflammatory); Group 2, mainly DcSSc, and interferon gamma (IFNʳ), IL-2, IL-4, IL-5, monocyte chemotactic protein
(MCP)-3, IL-12p40 and IL-12p70 high (T lymphocyte, adaptive inflammatory); Group3, LcSSc and DcSSc, low levels of cytokines and chemokines
(quiescent). Plasma analysis did not clearly cluster and in general did not correlate with the blister fluid analysis. EGF, epidermal growth factor; FGF,
fibroblast growth factor; GCSF, granulocyte colony-stimulating factor; GMCSF, granulocyte–macrophage colony-stimulating factor; IL-1RA, interleukin-1
receptor antagonist, MIP, macrophage inflammatory protein; PDGF, platelet-derived growth factor; RANTES, regulated on activation normal T cell
expressed and secreted; TGFʲ, transforming growth factor beta; VEGF, vascular endothelial cell growth factor.
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IL-6, IL-10, tumour necrosis factor alpha and IL-1ʱ high
(innate inflammatory IL-6 associated), Group 2 by in-
creased concentrations of interferon gamma (IFNʳ), IL-2,
IL-4, IL-5, MCP-3, IL12p40, IL12p70 (IFNʳ Th cell
group), and Group 3 by low levels of cytokines and che-
mokines (quiescent group). Plasma hierarchical clustering
did not correlate with the blister fluid analysis (Figure 1b).
A group of diffuse SSc patients was found to cluster in the
plasma analysis but there was no correlation between this
and the groups seen in blister fluid analysis.
Analysis of the clinical and laboratory characteristics
of the patients is presented in Table 4, showing Group 1
to be early DcSSc with higher skin scores, Group 2 to be
late-stage DcSSc, and that Group 3 contained LcSSc or
DcSSc with low skin score. There was no apparent dif-
ference in antibody profiles, internal organ involvement
or immunotherapy between the three groups. Matched
plasma and blister fluid samples did not cluster together
for individual patients (data not shown).
Network analysis
Using the STRING 9.1 database, a network of potential
protein interactions was developed according to the
subgroups derived from the hierarchical clustering
(Figure 2a,b). Group 1 is characterised by IL-6 innate in-
flammatory protein pattern, with IL-6 occupying a central
node with multiple downstream protein interactions. In
Group 2 protein interactions, IFNʳ appears as a central
cytokine with multiple related immune and inflammatory
proteins.
Discussion
Skin involvement in SSc remains a challenging clinical
problem in part because therapies need to be tested
against reliable biomarkers of the local disease process.
Our work has confirmed the feasibility of multiplex pro-
filing of blister fluid, and overall the results are consist-
ent with an inflammatory disease microenvironment in
which T-cell responses as well as proangiogenic stimuli
are being induced. The results of plasma analysis have
shown a distinct pattern of systemic inflammation, which
does not overlap with the blister fluid analysis. The blister
fluid profiling may be giving an insight into the local
pathological process within the local dermal tissue envir-
onment, as described previously by Søndergaard and col-
leagues [6]. SSc is a multisystem and multisite disease, and
the results from the serum are likely to reflect this. The
blister fluid allows us to profile the disease more locally,
and allows for clearer interpretation of the data as we are
only sampling from one organ. Søndergaard and col-
leagues have already shown that the blister fluid is acellu-
lar [6], and differences in albumin concentrations support
our finding that the blister fluid is from the local
environment and not drawn out from the plasma. More
specifically, we found increased IL-6 in the blister fluid of
our DcSSc patients, which supports earlier work by Khan
and colleagues [8]. The hierarchical analysis of the blister
fluid also identified a subgroup of patients who seem to
have an innate inflammatory IL-6 associated profile within
the dermis. Tocilizumab, a monoclonal antibody against
IL-6, is currently undergoing trials as a potential targeted
treatment in DcSSc patients with evidence of significantly
affected skin disease, estimated using the modified Rodnan
skin score and raised platelets. This method of profiling
patients may help to aid identification of those who are
likely to be more responsive to this treatment.
Downstream of IL-6, and in the presence of profibrotic
transforming growth factor beta, Th17 responses are in-
duced and are now believed to be important in the devel-
opment of autoimmune inflammatory disorders including
SSc [9]. Anti-IL-17 therapy has now been shown of benefit
in some conditions, including psoriasis and ankylosing
spondylitis [10,11]. However, inflammatory bowel disease
was seen to worsen following anti-IL-17 consistent with a
gut-specific protective role for IL-17 [12]. We found that
IL-17, which was undetectable in HC samples, was in-
duced in a subset of diffuse SSc patients, consistent with
local Th17 polarisation. However, how important IL-17 is
in promoting fibrosis and inflammation in SSc, and
whether this subset of patients would benefit from anti-
IL-17 targeted therapy, remain to be clarified. Several
candidate treatment approaches in SSc are predicted to
modulate Th17 function (halofuginone, tocilizumab)
and agents targeting this factor are already in clinical
use for psoriasis.
FGF-2 is an angiogenic factor induced by hypoxia,
which usually results in increased angiogenesis [13]. We
found that FGF-2 was increased in the SSc blister fluid,
compared with HCs. There is a paradox in SSc where
angiogenic factors are overexpressed, but the normal
vascular repair seen in response to hypoxia and damage
does not occur. FGF-2 could be involved in the deregu-
lated vascular repair seen in SSc.
The results also support a role for PDGF in the SSc
skin lesions where this factor may be acting as a chemo-
attractant and mitogen for fibroblasts. Clinical trials
inhibiting PDGF tyrosine kinase receptor with imatinib
have not been conclusive regarding whether it is PDGF
that recruits fibroblasts to the activated areas of skin,
but again patients could be stratified based on the der-
mal level of this factor [14].
The concentration of MCP-3 was also significantly in-
creased in SSc blister fluid compared with HCs. This
chemokine has previously been identified as a key medi-
ator in skin fibrosis in SSc, and in the type 1 tight-skin
mouse [15], and also correlated with the extent of skin
sclerosis and the severity of lung fibrosis [16]. We did
Clark et al. Arthritis Research & Therapy  (2015) 17:73  Page 7 of 11not find any correlation between MCP-3 concentrations
and skin score, which is a finding previously noted from
serum samples [16].
Limitations of this study include the low numbers of
patients studied from disease subsets, and the limited
number of proteins studied as well as their pleotropic
nature. However, an attempt has been made to cluster
patients into pathogenic groups based on the profile of
blister fluid protein expression. Using an unbiased ap-
proach three groups were identified, and then protein–
protein interaction software was used to describe the
pathogenic pathways in the active groups, showing an
IL-6-dominated inflammatory group, an IFNʳ-associated
inflammatory group as well as a quiescent group. These
results have some parallel with the recent literature
where gene expression profiling of skin biopsy material
has been used to define mechanistic subgroups [17]. Of
interest, the IFNʳ inflammatory signature was seen in
the blister fluid of some patients with very longstanding
disease, and despite immunosuppressive therapy. In a
Table 4 Patient characteristic analysis according to blister fluid heat map clusters
Group by heat
map clustering
Diffuse/limited
patient
Disease duration
(years)
Skin score Antibodies Current therapy Past therapy Current steroid
Group 1 DcSSc17 8 24 fs, RNApol HCQ No
Interleukin-6 DcSSc20 1 27 nuc MMF Yes
DcSSc14 1 38 ACA MMF Yes
DcSSc19 5 28 fs, U3RNP HCQ Campath1 No
DcSSc16 2 34 hom, Scl70 MTX CYC Yes
LcSSc6 3 6 ACA No
DcSSc15 5 35 hom, Scl70+Ro MMF Yes
DcSSc18 15 24 hom, Scl70 HCQ No
Mean (SEM) 5 (1.7) 27 (3.5)
Group 2 LcSSc2 23 6 fs, Scl70+Ro HCQ, MMF Yes
Interferon gamma DcSSc1 10 16 crs, nRNP+Ro MMF, MTX CYC Yes
DcSSc9 33 28 nuc AZA MTX, MMF, CIC Yes
DcSSc4 11 30 hom, Scl70 MMF, IMI AZA, CYC No
DcSSc6 6 24 fs, RNA pol MMF, HCQ CYC Yes
DcSSc7 13 9 nuc, HCQ No
DcSSc11 2 34 hom, Scl70 MTX CYC Yes
DcSSc2 8 8 hom, Scl70 HCQ MMF No
DcSSc8 20 30 hom+nuc, Scl70 No
Mean (SEM) 14 (3.2) 21 (3.6)
Group 3 DcSSc10 3 12 nuc IVIG MMF Yes
Quiescent LcSSc1 6 4 ACA No
DcSSc3 8 15 fs, RNA pol MTX MMF Yes
DcSSc13 2 12 fs+cyto MTX Yes
DcSSc5 20 10 hom, Scl70 MMF CYC Yes
LcSSc5 12 15 fs No
DcSSc12 10 14 hom, Scl70 AZA CYC No
LcSSc3 3 6 ACA No
LcSSc4 4 6 fs+nuc MTX Yes
Mean (SEM) 7.5 (1.9) 10 (1.4)
Patients were grouped according to blister fluid heat map cluster. Patients in Group 1 (interleukin-6 high, innate inflammatory) were more likely to have early
DcSSc with high skin score, Group 2 (interferon gamma high, effector T cell) were mainly late stage DcSSc, and Group 3 (quiescent pattern) were more likely to be
LcSSc or DcSSc with low skin scores. Analysis of variance showed significant difference for disease duration between groups (P = 0.042) and skin score (P =0.003).
Scheffe post hoc analysis showed higher skin score in Group 1 compared with Group 3 (P= 0.005), otherwise P= not significant. Pattern of anti-nuclear antibody
staining: homogeneous (hom), fine speckled (fs), nucleolar (nuc), coarse speckled (crs), cytoplasmic pattern (cyto). Therapy: azathioprine (AZA), cyclophosphamide
(CYC), cyclosporine (CIC), hydroxychloroquine (HCQ), intravenous immunoglobulin (IVIG), mycophenolate (MMF), methotrexate (MTX). ACA, anticentromere
antibody; DcSSc, diffuse cutaneous systemic sclerosis; LcSSc, limited cutaneous systemic sclerosis; SEM, standard error of the mean.
Clark et al. Arthritis Research & Therapy  (2015) 17:73  Page 8 of 11recent elegant study, Gerber and colleagues have shown
that primary abnormalities of the extracellular matrix
can lead to inflammation and scleroderma-like auto-
immunity [18]. It is possible that the abnormalities of
the extracellular matrix are maintaining inflammatory
and autoimmune responses in late stage SSc.
Our work supports the idea of profiling patients early
in their disease via this minimally invasive technique.
Figure 2 Network string analysis derived from hierarchical clustering. (a) Using the STRING 9.1 database, a network of potential protein
interactions detected as increased in SSc dermal blister fluid of SSc patients clustered into Group 1. An innate inflammatory profile dominated
by interleukin (IL)-6 and its associated interactions, as well as regulatory IL-10, were found to be increased. (b) Network of proteins detected as
increased in the dermal blister fluid of SSc patients clustered into Group 2. Interferon gamma (IFNʳ) and effector T-lymphocyte associated protein
network predominates this subgroup. Light green, association by text mining; pink, association by experiment; black, association by co-expression;
dark green, association by neighbourhood. Group 3 was quiescent (data not shown).
Clark et al. Arthritis Research & Therapy  (2015) 17:73  Page 9 of 11This dermal suction blister method could be used to target
therapy towards the inflammatory profile of each patient.
If combined with longitudinal assessment, the method
could prove useful to predict disease progression and
organ involvement depending on the inflammatory profile
of the fluid, as well as response to treatments.
Potential biomarkers are under investigation to help
predict severity of disease and organ involvement [19].
The dermal suction blister method offers a unique op-
portunity to complement biomarker research, by helping
to discern whether the inflammatory profile is driven by
local factors in the skin or systemic effects.
Conclusions
Taken together, our findings confirm the feasibility and
potential utility of dermal blister fluid to define local
biological processes in SSc, and to identify profibrotic,
angiogenic and T-cell-derived factors expressed locally
within the skin lesions. In contrast, analysis of plasma
samples revealed elevation of monocyte-derived inflam-
matory proteins. Discordance between the interstitial
fluid samples and paired serum samples suggests that
the dermal blister sampling method reflects local dermal
protein expression. This dermal suction method offers
an opportunity to profile the local inflammatory process
occurring within the skin and has potential to comple-
ment clinical and gene expression-based classification to
facilitate targeted therapy, as well as providing potential
markers of disease activity or indicators of early treat-
ment effect in proof-of-mechanism studies.
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